Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis

Maria Angela Tosca; Roberta Olcese; Donata Girosi; Emilio Casalini; Marco Scaglione; Giorgio Ciprandi

doi:10.15586/aei.v51i3.786

Maria Angela Tosca

Allergy Clinic, IRCCS Giannina Gaslini, Genoa, Italy.

Roberta Olcese

Allergy Clinic, IRCCS Giannina Gaslini, Genoa, Italy.

Donata Girosi

Pediatric Pulmonology and Respiratory Endoscopy, IRCCS Giannina Gaslini, Genoa, Italy.

Emilio Casalini

Pediatric Clinic and Endocrinology, IRCCS Giannina Gaslini, Genoa, Italy.

Marco Scaglione

Allergy Clinic, IRCCS Giannina Gaslini, Genoa, Italy.

Giorgio Ciprandi

Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.

Keywords

Asthma, Atopic Dermatitis, Childhood, Dupilumab, Thyroid Function

Abstract

Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic.

Abstract 157 | PDF Downloads 133 HTML Downloads 16 XML Downloads 15

References

1. Alsaffar R, Alkholifi FK. Exploring the efficacy and contribution of Dupilumab in asthma management. Mol Immunol. 2022;146:9–17. 10.1016/j.molimm.2022.03.119

2. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines—Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5): 1023–42. 10.1111/all.14235

3. Yang YB, Gohari A, Lam J. Brief academic review and clinical practice guidelines for pediatric atopic dermatitis. Curr Pediatr Rev. 2021;17(3):229–37. 10.2174/1573396316999200820163434

4. Scott JB, Paller AS. Novel treatments for pediatric atopic dermatitis. Curr Opin Pediatr. 2021;33(4):392–401. 10.1097/MOP.0000000000001027

5. Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: A review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97–115. 10.18176/jiaci.0682

6. Narantsatsral D, Junko T, Hideyuki I, Daisuke I, Hiroyuki T, Yuka N, et al. Online ahead of print. Painless thyroiditis in a dupilumab-treated patient. Endocrinol Diabetes Metab Case Rep. 2020;2020:20–30. 10.1530/EDM-20-0030

7. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48. 10.1056/NEJMoa1610020

8. Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: Results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–70. 10.1111/bjd.19460

9. Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results through Week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3): 365–83. 10.1007/s40257-022-00683-2

10. Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: A review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97–115. 10.18176/jiaci.0682

11. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5–14. 10.1111/cea.13491

12. Katsuta M, Matsuxaki H, Yasuda KI, Kharma B, Nobeyama Y, et al. Transient Increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis. Acta Derm Venereol. 2021;101(6):adv00483. 10.2340/00015555-3842

13. Colin IM, Isaac J, Dupret P, Ledant T, D’Hautcourt JL. Functional lymphocyte subset assessment of the Th1/Th2 profile in patients with autoimmune thyroiditis by flow cytometric analysis of peripheral lymphocytes. J Biol Regul Homeost Agents. 2004;18:72–6.

14. Santaguida MG, Nardo S, Del Duca SC, Lococo E, Virili C, Gargano L, et al. Increased interleukin-4-positive lymphocytes in patients with Hashimoto’s thyroiditis and concurrent non-endocrine autoimmune disorders. Clin Exp Immunol. 2011; 165:148–54. 10.1111/j.1365-2249.2011.04419.x